These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 495334)

  • 41. Combined administration of a gonadotropin-releasing hormone antagonist and testosterone in men induces reversible azoospermia without loss of libido.
    Pavlou SN; Brewer K; Farley MG; Lindner J; Bastias MC; Rogers BJ; Swift LL; Rivier JE; Vale WW; Conn PM
    J Clin Endocrinol Metab; 1991 Dec; 73(6):1360-9. PubMed ID: 1955518
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Experiences with the antiestrogen tamoxifen in the therapy of oligozoospermia].
    Schill WB; Landthaler M
    Hautarzt; 1981 Jun; 32(6):306-8. PubMed ID: 7263237
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Semen quality and reproductive hormones before orchiectomy in men with testicular cancer.
    Petersen PM; Skakkebaek NE; Vistisen K; Rørth M; Giwercman A
    J Clin Oncol; 1999 Mar; 17(3):941-7. PubMed ID: 10071288
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The role of arginine, indomethacin and kallikrein in the treatment of oligoasthenospermia.
    Aydin S; Inci O; Alagöl B
    Int Urol Nephrol; 1995; 27(2):199-202. PubMed ID: 7591579
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Therapeutic results with tamoxifen in oligospermia. II. Hormonal analysis and semen parameters].
    Schieferstein G; Adam W; Armann J; Bantel E; Cörlin R; Egenrieder H; Fierlbeck G; Hook B; Schiek A; Schubring G
    Andrologia; 1987; 19(3):333-41. PubMed ID: 3115143
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effects of long-term treatment with human pure follicle-stimulating hormone on semen parameters and sperm-cell ultrastructure in idiopathic oligoteratoasthenozoospermia.
    Arnaldi G; Balercia G; Barbatelli G; Mantero F
    Andrologia; 2000 May; 32(3):155-61. PubMed ID: 10863970
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Oral kallikrein-therapy of asthenozoospermia].
    Kienitz T; Schill WB
    Fortschr Med; 1977 Sep; 95(34):2102-5. PubMed ID: 903074
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [The effect of kallikrein on sperm motility (author's transl)].
    Lunglmayr G
    Wien Klin Wochenschr; 1976 Nov; 88(21):709-11. PubMed ID: 1007281
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Kallikrein therapy in asthenozoospermia].
    Neumann J; Glander HJ; Schreiber G; Engel S
    Dermatol Monatsschr; 1985; 171(2):102-5. PubMed ID: 3845023
    [No Abstract]   [Full Text] [Related]  

  • 50. [Initial results in the treatment of male fertility disorders with kallikrein: asthenozoospermia].
    Schill WB
    Hautarzt; 1975 Aug; 26(8):430-2. PubMed ID: 1176289
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Insulin-like growth factor-I and alpha 2-macroglobulin in seminal plasma correlate with semen quality.
    Glander HJ; Kratzsch J; Weisbrich C; Birkenmeier G
    Hum Reprod; 1996 Nov; 11(11):2454-60. PubMed ID: 8981132
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effects of kallikrein on the male reproductive system and its use in the treatment of idiopathic oligozoospermia with impaired motility.
    Giovenco P; Amodei M; Barbieri C; Fasani R; Carosi M; Dondero F
    Andrologia; 1987 Jun; 19 Spec No():238-41. PubMed ID: 3651109
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Spermatogenesis after parathyroidectomy in patients with symptomatic secondary hyperparathyroidism.
    Chou FF; Lee CH; Lee CT; Huang FJ; Hsu KL
    J Am Coll Surg; 2003 Jun; 196(6):854-8. PubMed ID: 12788420
    [TBL] [Abstract][Full Text] [Related]  

  • 54. An inverse relationship exists between seminal plasma inhibin and serum follicle-stimulating hormone in man.
    Scott RS; Burger HG
    J Clin Endocrinol Metab; 1981 Apr; 52(4):796-803. PubMed ID: 6782118
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Successful kallikrein therapy of subfertile patients].
    Schütte B; Schirren C
    Fortschr Androl; 1978; 6():76-87. PubMed ID: 711080
    [No Abstract]   [Full Text] [Related]  

  • 56. Transferrin in seminal plasma and in serum of men: its correlation with sperm quality and hormonal status.
    Ber A; Vardinon N; Yogev L; Yavetz H; Homonnai ZT; Yust I; Paz GF
    Hum Reprod; 1990 Apr; 5(3):294-7. PubMed ID: 2112555
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Seminal plasma transferrin concentration: relationship with seminal parameters and plasma hormone levels.
    Fuse H; Satomi S; Okumura M; Katayama T
    Urol Int; 1992; 49(3):158-62. PubMed ID: 1466094
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Kallikrein treatment of male infertility.
    Sato H; Mochimaru F; Kobayashi T; Iizuka R; Kaneko S; Moriwaki C
    Adv Exp Med Biol; 1979; 120A():529-36. PubMed ID: 495333
    [No Abstract]   [Full Text] [Related]  

  • 59. Changes in seminal quality following oral zinc therapy.
    Kynaston HG; Lewis-Jones DI; Lynch RV; Desmond AD
    Andrologia; 1988; 20(1):21-2. PubMed ID: 3369705
    [TBL] [Abstract][Full Text] [Related]  

  • 60. In vitro kallikrein treatment of human spermatozoa: stimulation of sperm penetration into zona-free hamster eggs depends on the quality of initial semen parameters but not on constituents of the kallikrein-kinin system in seminal plasma.
    Sterzik K; Strehler E; Abt M; Rosenbusch B
    J Urol; 1994 Jun; 151(6):1712-4. PubMed ID: 8189602
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.